| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 10/22/2026 | ±5.7% | -11.8% | under-priced |
| 08/07/2026 | ±7.1% | +1.8% | over-priced |
| 04/23/2026 | ±2.8% | -2.6% | over-priced |
| 01/29/2026 | ±4.9% | +3.6% | over-priced |
| 10/24/2025 | ±4.2% | +2.8% | over-priced |
| 08/11/2025 | ±3.2% | +0.3% | over-priced |
| 04/25/2025 | ±4.3% | +0.7% | over-priced |
| 01/31/2025 | ±5.2% | +0.4% | over-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q1 FY2027 | $2.19 | $8.2B | $2.8B |
| Q4 FY2026 | — | $6.7B | $2.3B |
| Q3 FY2026 | $1.45 | $5.8B | $1.8B |
| Q2 FY2026 | $1.26 | $5.3B | $1.6B |
LRCX (LRCX) reports in 85 days, with the next report estimated for 01/20/2027. Across the last 8 reports, options priced an average ±4.7% earnings move while the stock actually moved 3.0% on average — the market has systematically over-priced LRCX's earnings risk. Fundamentals into the print: EPS up 76.6% year-over-year, revenue up 54.4%. QuantLogix's live 5-factor engine currently reads LRCX as a neutral at 48/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →